 | Up a level |
2020
Kater, Arnon P., Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter 
ORCID: 0000-0001-5617-4403, D'Rozario, James, Assouline, Sarit ORCID: 0000-0002-7638-1589, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R., Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn and Seymour, John F.
(2020).
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
J. Clin. Oncol., 38 (34).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
2018
Hillmen, Peter, Kater, Arnon P., Seymour, John Francis, Langerak, Anton W., Eichhorst, Barbara, Owen, Carolyn, Assouline, Sarit E., Janssens, Ann, Marlton, Paula, Badoux, Xavier C., Mous, Rogier, Chyla, Brenda, Humerickhouse, Rod, Boyer, Michelle, Humphrey, Kathryn, Jiang, Yanwen, Punnoose, Elizabeth, Wang, Jue, Wu, Qun Jenny and Mobasher, Mehrdad (2018). High, durable minimal residual disease negativity (MRD-) with venetoclax plus rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755